Pharmaceuticals are slow in the take-up of digital technology, concluded a panel discussion at MedCity CONVERGE . The industry is "generations" behind clinics in the use of digital, said Kottler , CEO of HealthPrize Technologies , noting Flatiron Health 's $ 1.9bn acquisition of HealthPrize Technologies as a sign that things are changing. Furthermore, Kottler partnered with Pear Therapeutics for digital solutions to supplement its drugs for schizophrenia and multiple sclerosis. Kottler cited depression and addiction as areas in which software could me more beneficial than drugs. Meanwhile, AI could help prevent the rising cost of drugs, said Derek Bowen from Kottler .
Pharmaceuticals are slow in the take-up of digital technology, concluded a panel discussion at MedCity CONVERGE. The industry is "generations" behind clinics in the use of digital, said Tom Kottler, CEO of HealthPrize Technologies, noting Roche's $1.9bn acquisition of Flatiron Health as a sign that things are changing. Furthermore, Novartis partnered with Pear Therapeutics for digital solutions to supplement its drugs for schizophrenia and multiple sclerosis. Kottler cited depression and addiction as areas in which software could me more beneficial than drugs. Meanwhile, AI could help prevent the rising cost of drugs, said Derek Bowen from Blackfynn.